You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the ADASUVE (loxapine) Drug Profile, 2024 PDF Report in the Report Store ~

ADASUVE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Generic Entry Outlook for Adasuve

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADASUVE?
  • What are the global sales for ADASUVE?
  • What is Average Wholesale Price for ADASUVE?
Drug patent expirations by year for ADASUVE
Drug Prices for ADASUVE

See drug prices for ADASUVE

Recent Clinical Trials for ADASUVE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lee's Pharmaceutical LimitedPhase 3
University of ArkansasPhase 4
Mount Sinai Hospital, ChicagoPhase 4

See all ADASUVE clinical trials

US Patents and Regulatory Information for ADASUVE

ADASUVE is protected by five US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADASUVE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 ⤷  Subscribe ⤷  Subscribe
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 ⤷  Subscribe ⤷  Subscribe
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ADASUVE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Ferrer Internacional S.A. Adasuve loxapine EMEA/H/C/002400
Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
Authorised no no no 2013-02-20
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ADASUVE

See the table below for patents covering ADASUVE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2096374 Unité de chauffage autonome et unité d'administration d'un médicament utilisant une telle unité de chauffage (Self-contained heating unit and drug-supply unit employing same) ⤷  Subscribe
European Patent Office 1392263 ADMINISTRATION D'AEROSOLS CONTENANT DE PETITES PARTICULES VIA UNE VOIE D'INHALATION (DELIVERY OF AEROSOLS CONTAINING SMALL PARTICLES THROUGH AN INHALATION ROUTE) ⤷  Subscribe
Japan 2004536805 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ADASUVE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1389098 1390040-2 Sweden ⤷  Subscribe PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
1389098 300609 Netherlands ⤷  Subscribe PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098 C300609 Netherlands ⤷  Subscribe PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

ADASUVE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for ADASUVE

Introduction

ADASUVE, developed by Alexza Pharmaceuticals, is an innovative inhalation powder of loxapine designed to treat acute agitation in adults with schizophrenia or bipolar I disorder. This article delves into the market dynamics and financial trajectory of ADASUVE, highlighting its commercial prospects, challenges, and the impact on Alexza Pharmaceuticals.

Commercial Prospects of ADASUVE

Approval and Launch

ADASUVE received FDA and EU approval for the acute treatment of agitation in adults with schizophrenia or bipolar I disorder. The drug was launched in Germany by Ferrer and was expected to be launched in the US by Teva in Q1 2014[1].

Market Positioning

ADASUVE offers significant advantages over traditional oral medications, including rapid onset of action and ease of administration. These benefits are crucial in medical emergency settings, where quick and reliable treatment is essential. The drug demonstrated a statistically significant decrease in agitation within 10 minutes of dosing, with sustained improvement over 2 hours[4].

Pricing Strategy

Despite a premium price of $75-100 per dose, compared to less than $10 for most oral drugs, the rapid effect and dosing convenience of ADASUVE were expected to drive product uptake. The pricing strategy was based on the drug's unique benefits and the potential to reduce overall treatment costs by minimizing the need for repeated dosing and reducing the time spent in emergency settings[1].

Financial Performance

Revenue Projections

Initial projections suggested that ADASUVE could achieve global sales of over $200 million by 2018, with a peak market share of 20%[1]. By 2022, peak global revenue was estimated to reach $230 million, with sustained profitability anticipated from 2016[1].

Quarterly Financial Results

In the first quarter of 2016, Alexza reported revenues of $0.7 million, primarily from product sales to Teva and Ferrer, as well as royalty revenues. This was consistent with the previous year's figures. However, the company's net loss increased to $3.4 million from $0.4 million in the same period in 2015, largely due to changes in the contingent liability fair value model and the suspension of commercial ADASUVE production operations in 2015[2].

Cost Structure

Research and development expenses decreased by $1.4 million in the first quarter of 2016 compared to the same period in 2015, mainly due to the company's restructuring strategy and reduction in employee headcount. General and administrative expenses also saw a decline from $3.7 million to $2.4 million during the same period[2].

Challenges and Setbacks

Respiratory Concerns

Although ADASUVE demonstrated minimal respiratory toxicity risk, the FDA required a REMS (Risk Evaluation and Mitigation Strategy) protocol due to higher respiratory events in patients with active airway disease. This could potentially deter some physicians and facilities from using the drug, although the risk was considered minimal[1].

Partnership and Production Issues

Alexza Pharmaceuticals faced significant challenges when its partnership with Teva ended in 2015. The company announced plans to reacquire the rights to ADASUVE, which led to the suspension of commercial production operations. This decision had a substantial impact on the company's financial performance and market trajectory[5].

Valuation and Investment Case

Net Present Value (NPV) Calculation

The net present value (NPV) for ADASUVE and another product candidate, AZ-002 (Staccato alprazolam), was estimated at $85 million. Adding $32 million in net cash, this resulted in a valuation of $6.77 per share for Alexza Pharmaceuticals, indicating significant upside potential compared to the then-current share price of $4.32[1].

Staccato Platform Technology

The Staccato inhalation delivery platform, underlying ADASUVE, was seen as a valuable asset with potential applications in other pharmaceutical ingredients. This technology presented additional value-creation opportunities, although it was not specifically valued in the initial assessment[1].

Future Development and Pipeline

AZ-002 and Other Candidates

In addition to ADASUVE, Alexza was advancing AZ-002 as a treatment candidate for acute repetitive seizures in epilepsy patients. A Phase II study was expected to start in the second half of 2013, with further development candidates potentially announced in the first half of 2014[1].

Key Takeaways

  • Rapid Onset and Convenience: ADASUVE's quick effect and ease of administration positioned it as a key agent for treating acute agitation.
  • Financial Performance: Despite initial revenue projections, the company faced financial challenges, including increased net losses and the suspension of commercial production.
  • Challenges: Respiratory concerns and the end of the partnership with Teva were significant setbacks.
  • Valuation: The NPV calculation indicated upside potential, and the Staccato platform technology offered additional value-creation opportunities.
  • Future Development: Alexza continued to develop other products using the Staccato platform, including AZ-002.

FAQs

What is ADASUVE used for?

ADASUVE is used for the acute treatment of agitation in adults with schizophrenia or bipolar I disorder.

What are the key benefits of ADASUVE?

ADASUVE offers a rapid onset of action and ease of administration, making it a valuable option in medical emergency settings.

Why did Alexza Pharmaceuticals suspend commercial production of ADASUVE?

Commercial production was suspended due to the end of the partnership with Teva and the subsequent reacquisition of rights by Alexza Pharmaceuticals.

What is the Staccato platform technology?

The Staccato platform is a proprietary inhalation delivery system developed by Alexza Pharmaceuticals, which provides rapid and efficient drug delivery.

How did the financial performance of Alexza Pharmaceuticals change after the launch of ADASUVE?

The company reported increased net losses and a decline in research and development expenses following the suspension of commercial production and the end of the partnership with Teva.

Sources

  1. Edison Investment Research: "Alexza Pharmaceuticals - Edison Investment Research" (August 27, 2013)
  2. PR Newswire: "Alexza Reports 2016 First Quarter Financial Results" (May 11, 2016)
  3. PR Newswire: "Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer" (September 30, 2024)
  4. ADASUVE Formulary Kit Monograph: "ADA-50102 with current PI inserted v5.indd - ADASUVE"
  5. BioSpace: "Alexza Pharma and Teva Break Up Over Adasuve" (November 2, 2015)

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.